login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VIRIOS THERAPEUTICS INC (VIRI) Stock News
USA
- NASDAQ:VIRI -
US92829J1043
-
Common Stock
0.155
USD
+0.02 (+12.4%)
Last: 10/8/2024, 8:00:02 PM
0.1452
USD
-0.01 (-6.32%)
After Hours:
10/8/2024, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VIRI Latest News, Press Relases and Analysis
All
Press Releases
a year ago - By: Benzinga
- Mentions:
EXAI
BIOR
NXL
RHE
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
a year ago - By: Halper Sadeh LLC
- Mentions:
B
NAPA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders
a year ago - By: Benzinga
- Mentions:
GRI
TRIB
BPTH
SAGE
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
a year ago - By: InvestorPlace
VIRI Stock Earnings: Virios Therapeutics Beats EPS for Q2 2024
a year ago - By: Halper Sadeh LLC
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders
a year ago - By: Virios Therapeutics
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces Second Quarter 2024 Financial Results
a year ago - By: Virios Therapeutics
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
a year ago - By: InvestorPlace
- Mentions:
GTBP
MMV
Why Is Virios Therapeutics (VIRI) Stock Down 44% Today?
a year ago - By: InvestorPlace
VIRI Stock Earnings: Virios Therapeutics Misses EPS for Q1 2024
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
a year ago - By: InvestorPlace
- Mentions:
NVDA
JAGX
Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain?
a year ago - By: InvestorPlace
- Mentions:
JAGX
GTBP
MMV
Why Is Jaguar Health (JAGX) Stock Down 40% Today?
a year ago - By: InvestorPlace
- Mentions:
MMV
GTBP
FFIE
TANH
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
a year ago - By: Virios Therapeutics
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: Virios Therapeutics
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
2 years ago - By: Virios Therapeutics
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Please enable JavaScript to continue using this application.